Curaleaf Holdings Future Growth

Future criteria checks 1/6

Curaleaf Holdings is forecast to grow earnings and revenue by 77.6% and 12.4% per annum respectively. EPS is expected to grow by 75.3% per annum. Return on equity is forecast to be 17.6% in 3 years.

Key information

77.6%

Earnings growth rate

75.3%

EPS growth rate

Pharmaceuticals earnings growth	72.1%
Revenue growth rate	12.4%
Future return on equity	17.6%
Analyst coverage	Good
Last updated	11 Jul 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively

Jul 19

Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%

Jun 14

Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Jan 19

Earnings and Revenue Growth Forecasts

TSX:CURA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,770	37	88	203	4
12/31/2025	1,547	-70	150	197	12
12/31/2024	1,406	-153	87	177	14
3/31/2024	1,353	-237	46	111	N/A
12/31/2023	1,347	-230	5	75	N/A
9/30/2023	1,338	-343	1	79	N/A
6/30/2023	1,330	-312	-26	77	N/A
3/31/2023	1,312	-268	-127	9	N/A
12/31/2022	1,275	-258	-88	46	N/A
9/30/2022	1,244	-157	-137	22	N/A
6/30/2022	1,234	-202	-150	11	N/A
3/31/2022	1,232	-223	-170	-7	N/A
12/31/2021	1,196	-206	-230	-58	N/A
9/30/2021	1,118	-164	-201	-27	N/A
6/30/2021	984	-90	-237	-89	N/A
3/31/2021	790	-57	-127	8	N/A
12/31/2020	627	-57	-114	12	N/A
9/30/2020	472	-52	-110	-25	N/A
6/30/2020	351	-50	-86	5	N/A
3/31/2020	282	-72	-110	-23	N/A
12/31/2019	221	-67	-120	-38	N/A
9/30/2019	178	-57	-124	-37	N/A
6/30/2019	137	-84	-121	-50	N/A
3/31/2019	103	-64	-101	-45	N/A
12/31/2018	77	-56	-78	-33	N/A
9/30/2018	51	-40	-49	-20	N/A
6/30/2018	36	-6	-33	-10	N/A
3/31/2018	25	-3	-25	-10	N/A
12/31/2017	19	-3	N/A	-8	N/A
12/31/2016	4	0	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CURA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CURA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CURA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CURA's revenue (12.4% per year) is forecast to grow faster than the Canadian market (7.3% per year).

High Growth Revenue: CURA's revenue (12.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CURA's Return on Equity is forecast to be low in 3 years time (17.6%).

Curaleaf Holdings Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 36%

Consensus EPS estimates fall by 66%

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

No longer forecast to breakeven

Recent updates

These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively

Curaleaf Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%

Executive Vice-Chairman recently sold CA$706k worth of stock

Consensus EPS estimates fall by 17%

Curaleaf Holdings, Inc. (TSX:CURA) completed the acquisition of Northern Green Canada Inc. (NGC).

Curaleaf Holdings, Inc., Annual General Meeting, Jun 14, 2024

Curaleaf Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

Curaleaf Holdings, Inc. (TSX:CURA) signed a deal to acquire Northern Green Canada Inc. (NGC).

Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Curaleaf Expands Zero Proof™ Brand Portfolio with Launch of Stir Fast-Acting THC Beverage Mix

Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 36%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Curaleaf Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Executive Vice-Chairman recently sold CA$860k worth of stock

Is Curaleaf Holdings (CSE:CURA) Using Too Much Debt?

Curaleaf Expands Brand Portfolio with Launch of Zero Proof ™ Cannabis-Infused Drinkables

Curaleaf Holdings, Inc., Annual General Meeting, Oct 04, 2023

Curaleaf Holdings, Inc.'s Select™ Brand Expands Product Offerings With Launch of Select Liquid Diamonds

Second quarter 2023 earnings: EPS misses analyst expectations

Curaleaf Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Curaleaf Holdings, Inc. Unveils Strategic National Rebrand of Select

New minor risk - Shareholder dilution

Curaleaf Holdings (CSE:CURA) Has Debt But No Earnings; Should You Worry?

Consensus EPS estimates fall by 66%

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Less than half of directors are independent

Curaleaf Holdings, Inc. Announces Closure of Operations in California, Colorado and Oregon

Forecast to breakeven in 2025

Less than half of directors are independent

Curaleaf Holdings, Inc. Announces Expansion of BlueKudu Infused Chocolate Flavors Available on Florida Retail Menus

Curaleaf Holdings, Inc. Announces the Launch of Adult-Use Sales At Its Bordentown, New Jersey Location

Curaleaf Holdings Relocates Deerfield, IL Dispensary and Opens Doors to Adult-Use Customers

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) completed the acquisition of Tryke Companies, LLC for approximately $180 million.

Executive Vice-Chairman recently sold CA$160k worth of stock

We Think Curaleaf Holdings (CSE:CURA) Is Taking Some Risk With Its Debt

No longer forecast to breakeven

Consensus EPS estimates fall by 42%

No longer forecast to breakeven

Curaleaf Holdings, Inc., Annual General Meeting, Sep 08, 2022

Curaleaf Holdings, Inc. Announces Management Appointments

Curaleaf Holdings, Inc. Launches Plant Precision, New Product Line Targeting Specific Health and Wellness Categories

Consensus forecasts updated

Curaleaf Holdings, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden

First quarter 2022 earnings: EPS exceeds analyst expectations

Curaleaf Holdings, Inc. Reports Impairment Loss for the Quarter Ended March 21, 2022

Curaleaf Holdings, Inc. Announces Executive Changes

Consensus forecasts updated

Forecast breakeven date pushed back to 2023

Curaleaf Holdings, Inc Expands Product Offerings With Launch of BlueKudu Chocolates in Florida

Curaleaf Holdings, Inc., Annual General Meeting, Jun 23, 2022

Curaleaf Holdings, Inc. Announces its Select Brand Launches Limited-Edition Cliq Elite Live Strain in California

Curaleaf Holdings, Inc. to Report Q1, 2022 Results on May 09, 2022

Interim Chief Financial Officer exercised options to buy CA$851k worth of stock.

Curaleaf Holdings, Inc. Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Curaleaf Holdings, Inc. (CNSX:CURA) completed the acquisition of Bloom Dispensaries.

Curaleaf Holdings, Inc. (CNSX:CURA) entered into a definitive agreement to acquire Bloom Dispensaries for approximately $210 million.

Curaleaf Holdings, Inc. (CNSX:CURA) agreed to acquire Natural Remedy Patient Center, LLC for $13 million.

Curaleaf Holdings, Inc. announced that it has received $475 million in funding

Curaleaf Holdings, Inc. Launches Select X Bites

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.015 loss in 3Q 2020)

Is Curaleaf Holdings (CSE:CURA) A Risky Investment?

Director recently sold CA$1.4m worth of stock